American Heart Association

NewAmsterdam Pharma announced positive Phase 3 TANDEM trial results, showing obicetrapib and ezetimibe fixed-dose combo significantly reduced LDL-C by 48.6% vs. placebo at day 84, supporting global regulatory filings.

Phase III BROOKLYN trial results presented at AHA 2024 show obicetrapib significantly reduces LDL cholesterol in HeFH patients, with 34% achieving >50% reduction. Obicetrapib also lowers Lp(a) by 54.3% and raises HDL cholesterol, with no serious adverse events reported.

The Phase III BROOKLYN trial presented at AHA 2024 showed obicetrapib significantly reduced LDL cholesterol by 41.5% at 365 days, with 34% of patients achieving >50% reduction. Obicetrapib also lowered Lp(a) by 54.3%, addressing unmet need in dyslipidemia treatment.

Newly diagnosed heart failure patients with atrial fibrillation (A-fib) have a poor prognosis, prompting researchers to urge doctors to screen for A-fib. Patients with A-fib and heart failure with reduced ejection fraction (HFrEF) face particularly poor outcomes, necessitating more aggressive treatment regimens.

Stephen Nicholls presented Phase II trial findings on Eli Lilly’s muvalaplin, an oral inhibitor targeting Lp(a), at the AHA 2024 conference. Muvalaplin showed up to 85.8% reduction in Lp(a) levels, with higher doses (60mg, 240mg) demonstrating robust effects. The study highlighted challenges in measuring Lp(a) impact using traditional methods. Muvalaplin also reduced apoB and LDL cholesterol, and oxidized phospholipids. KOLs emphasized muvalaplin as the first oral therapy for Lp(a), potentially generating $17.82 billion by 2032.

HMRI researchers reduced stroke size by 74% using empagliflozin, an antidiabetic drug, in preclinical models, presenting findings at AHA Scientific Sessions. The study suggests potential preventive and acute treatment applications for high-risk individuals, though further research is needed.

Abbott announced new data supporting its Amplatzer Amulet LAA occluder system, showing benefits in treating AFib patients at risk of stroke. Five-year data demonstrates Amulet helps more patients avoid long-term blood-thinning medication compared to Boston Scientific’s Watchman device. The study, presented at AHA’s Scientific Sessions 2024, highlights Amulet’s long-lasting outcomes, effective LAA closure, and reduced need for blood-thinning medication.

Phase II trial results of Silence Therapeutics’ zerlasiran, presented at AHA 2024, show 80-85% reduction in Lp(a) levels and 25-30% reduction in LDL-C with well-tolerated, infrequent dosing, addressing unmet need for Lp(a)-targeted therapies.

NewAmsterdam Pharma announced additional Phase 3 BROOKLYN trial results for obicetrapib, showing significant LDL-C, Lp(a), and LDL particle reductions in HeFH patients on maximally tolerated lipid-lowering therapy, with safety comparable to placebo.